Serum levels of interleukin-9 correlate with negative prognostic factors in extranodal NK/T-cell lymphoma

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Zhang, Jing ^a,b   Wang, Wei Da ^a   Geng, Qi Rong ^a   Wang, Liang ^a   Chen, Xiao Qin ^a   Liu, Cheng Cheng ^a   Lv, Yue ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b HUBEI CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; INTERLEUKIN 9; METHOTREXATE; OXALIPLATIN; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; BLOOD; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERLEUKIN-9; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 84899509396     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094637     Document Type: Article

References (39)

1. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, et al. (2009) Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 113: 3931-3937.
2. Lee J, Suh C, Park YH, Ko YH, Bang SM, et al. (2006) Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 24: 612-618. (Pubitemid 46630424)
3. Sun J, Yang Q, Lu Z, He M, Gao L, et al. (2012) Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol 138: 429-434.
4. Moriai S, Takahara M, Ogino T, Nagato T, Kishibe K, et al. (2009) Production of interferon-{gamma}-inducible protein-10 and its role as an autocrine invasion factor in nasal natural killer/T-cell lymphoma cells. Clin Cancer Res 15: 6771-6779.
5. Teruya-Feldstein J, Jaffe ES, Burd PR, Kanegane H, Kingma DW, et al. (1997) The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. Blood 90: 4099-4105. (Pubitemid 27484065)
6. Nagato T, Kobayashi H, Kishibe K, Takahara M, Ogino T, et al. (2005) Expression of interleukin-9 in nasal natural killer/T-cell lymphoma cell lines and patients. Clin Cancer Res 11: 8250-8257. (Pubitemid 41746934)
7. Noelle RJ, Nowak EC (2010) Cellular sources and immune functions of interleukin-9. Nat Rev Immunol 10: 683-687.
8. Fischer M, Bijman M, Molin D, Cormont F, Uyttenhove C, et al. (2003) Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma. Leukemia 17: 2513-2516. (Pubitemid 38072592)
9. Qiu L, Lai R, Lin Q, Lau E, Thomazy DM, et al. (2006) Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood 108: 2407-2415. (Pubitemid 44497526)
10. Merz H, Houssiau FA, Orscheschek K, Renauld JC, Fliedner A, et al. (1991) Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin's disease and large cell anaplastic lymphoma. Blood 78: 1311-1317.
11. Li H, Nourbakhsh B, Ciric B, Zhang GX, Rostami A (2010) Neutralization of IL-9 ameliorates experimental autoimmune encephalomyelitis by decreasing the effector T cell population. J Immunol 185: 4095-4100.
12. Cheng G, Arima M, Honda K, Hirata H, Eda F, et al. (2002) Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med 166: 409-416. (Pubitemid 34864436)
13. Steenwinckel V, Louahed J, Orabona C, Huaux F, Warnier G, et al. (2007) IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells. J Immunol 178: 3244-3251. (Pubitemid 46333207)
14. Demoulin JB, Van Snick J, Renauld JC (2001) Interleukin-9 (IL-9) induces cell growth arrest associated with sustained signal transducer and activator of transcription activation in lymphoma cells overexpressing the IL-9 receptor. Cell Growth Differ 12: 169-174. (Pubitemid 32678002)
15. Shang Y, Kakinuma S, Amasaki Y, Nishimura M, Kobayashi Y, et al. (2008) Aberrant activation of interleukin-9 receptor and downstream Stat3/5 in primary T-cell lymphomas in vivo in susceptible B6 and resistant C3H mice. In Vivo 22: 713-720.
16. Demoulin JB, Uyttenhove C, Lejeune D, Mui A, Groner B, et al. (2000) STAT5 activation is required for interleukin-9-dependent growth and transformation of lymphoid cells. Cancer Res 60: 3971-3977. (Pubitemid 32204594)
17. Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, et al. (2013) First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer 119: 348-355.
18. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, et al. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17: 1244.
19. Hultner L, Druez C, Moeller J, Uyttenhove C, Schmitt E, et al. (1990) Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9). Eur J Immunol 20: 1413-1416. (Pubitemid 20206111)
20. Nicolaides NC, Holroyd KJ, Ewart SL, Eleff SM, Kiser MB, et al. (1997) Interleukin 9: a candidate gene for asthma. Proc Natl Acad Sci U S A 94: 13175-13180. (Pubitemid 27518495)
21. Levitt RC, McLane MP, MacDonald D, Ferrante V, Weiss C, et al. (1999) IL-9 pathway in asthma: new therapeutic targets for allergic inflammatory disorders. J Allergy Clin Immunol 103: S485-491.
22. Shimbara A, Christodoulopoulos P, Soussi-Gounni A, Olivenstein R, Nakamura Y, et al. (2000) IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J Allergy Clin Immunol 105: 108-115. (Pubitemid 30059110)
23. Knoops L, Renauld JC (2004) IL-9 and its receptor: from signal transduction to tumorigenesis. Growth Factors 22: 207-215. (Pubitemid 40123399)
24. Koo GC, Tan SY, Tang T, Poon SL, Allen GE, et al. (2012) Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov 2: 591-597.
25. Bouchekioua A, Scourzic L, de Wever O, Zhang Y, Cervera P, et al. (2014) JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia 28: 338-348.
26. Renauld JC, Vink A, Louahed J, Van Snick J (1995) Interleukin-9 is a major anti-apoptotic factor for thymic lymphomas. Blood 85: 1300-1305.
27. Lange K, Uckert W, Blankenstein T, Nadrowitz R, Bittner C, et al. (2003) Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. Oncogene 22: 517-527. (Pubitemid 36188609)
28. Lv X, Feng L, Fang X, Jiang Y, Wang X (2013) Overexpression of IL-9 receptor in diffuse large B-cell lymphoma. Int J Clin Exp Pathol 6: 911-916.
29. Kelleher K, Bean K, Clark SC, Leung WY, Yang-Feng TL, et al. (1991) Human interleukin-9: genomic sequence, chromosomal location, and sequences essential for its expression in human T-cell leukemia virus (HTLV)-I-transformed human T cells. Blood 77: 1436-1441.
30. Kassel SH, Echevarria RA, Guzzo FP (1969) Midline malignant reticulosis (so-called lethal midline granuloma). Cancer 23: 920-935.
31. Eichel BS, Harrison EG Jr, Devine KD, Scanlon PW, Brown HA (1966) Primary lymphoma of the nose including a relationship to lethal midline granuloma. Am J Surg 112: 597-605.
32. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, et al. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84: 1361-1392. (Pubitemid 24273002)
33. Jaffe ES, Chan JK, Su IJ, Frizzera G, Mori S, et al. (1996) Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 20: 103-111.
34. Yang L, Aozasa K, Oshimi K, Takada K (2004) Epstein-Barr virus (EBV)-encoded RNA promotes growth of EBV-infected T cells through interleukin-9 induction. Cancer Res 64: 5332-5337. (Pubitemid 39006553)
35. Lv X, Wang X (2013) The role of interleukin-9 in lymphoma. Leuk Lymphoma 54: 1367-1372.
36. Lu Y, Hong S, Li H, Park J, Hong B, et al. (2012) Th9 cells promote antitumor immune responses in vivo. J Clin Invest 122: 4160-4171.
37. Purwar R, Schlapbach C, Xiao S, Kang HS, Elyaman W, et al. (2012) Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 18: 1248-1253.
38. Li H, Rostami A (2010) IL-9: basic biology, signaling pathways in CD4+ T cells and implications for autoimmunity. J Neuroimmune Pharmacol 5: 198-209.
39. Yang XR, Pfeiffer RM, Wheeler W, Yeager M, Chanock S, et al. (2009) Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. Int J Cancer 125: 2912-2917.